Editas Medicine has an exclusive multimillion-dollar license with Juno Therapeutics to develop T cell therapies

in 2011, Rachel and I founded a company called Caribou Biosciences to commercialize the Cas proteins.

PGD has also been used for other controversial purposes, such as the birth if so-called savior siblings, destined from the moment of implantation not only to live their own lives, but also to serve as organ or cell donors for a sibling.

we founded Editas Medicine with $43 million in financing from three venture capital firms.